Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen. However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine. To help put this debate into context, here is a new educational video that helps explain how prescription drug costs are really determined and where the pharmaceutical dollar actually goes.Continue reading
Author Archive: AZBio
New study reviews unregulated stem cell clinics in six SW states
Expertise of providers, legitimacy of therapies examined
Aug. 1, 2019, Tempe, Arizona — Unproven and unregulated stem cell therapies for treatments for conditions ranging from Parkinson’s disease to multiple sclerosis to macular degeneration are putting patients at risk in a market that has grown rapidly in recent years.Continue reading
UA Researcher and Doctoral Student Reconcile Scientific Standoff in Colon Cancer Research
Curtis Thorne, PhD, and UA doctoral student Carly Cabel validated findings from a 2018 collaborative study that identified a possible new therapeutic target for colon cancer – after a Harvard lab challenged the initial results.Continue reading
Castle Biosciences IPO raises $73.6 Million
Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares.
Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
The company is headquartered in Friendswood, Texas and has Laboratory/Clinical Operations in Phoenix, Arizona.
DARPA grants ASU up to $38.8 million to create epigenetic tool for fight against weapons of mass destruction
Arizona State University announced today that it has been selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to build a field-deployable, point-of-care device that will determine in 30 minutes or less if a person has been exposed to weapons of mass destruction or their precursors. The DARPA award, worth up to $38.8 million over four years in phases and options, will build on the university’s growing capabilities in developing molecular diagnostics for applications in defense and human health.Continue reading
Study reveals genetic similarities of osteosarcoma between dogs and children
TGen and Tufts University novel findings for this deadly bone cancer could lead to better treatments for people and pets
Continue reading
In the Crowded Consumer Health App Market, Investors Advise CEOs on How to Stand Out From the Rest
With more people turning to their smartphones to complement their medical care, and the number of apps flooding the marketplace, how can a new consumer health app catch the attention of investors?Continue reading
Amgen And Allergan’s MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
First Biosimilar Avastin® and Herceptin® Products to Launch in the United StatesContinue reading